Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: A phase II trial of the NSABP foundation research group

Priya Rastogi, Marc E. Buyse, Sandra M. Swain, Samuel A. Jacobs, André Robidoux, Marcia K. Liepman, Eduardo R. Pajon, Philip A. Dy, Juan G. Posada, Marianne K. Melnik, Fanny Piette, Charles E. Geyer, Elfetherios P. Mamounas, Norman Wolmark

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: A phase II trial of the NSABP foundation research group'. Together they form a unique fingerprint.

Medicine & Life Sciences